Safety
Cancer
ADVERSE EVENTS, ADVERSE EVENT, CANCER
Neoadjuvant camrelizumab plus nab-paclitaxel and capecitabine did not cause any previously unreported TRAEs (Table Summary of treatment-related adverse eventsAll adverse events were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0